Alligator Bioscience
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
ATORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000767188 (+8 more)
- LEI:
- 549300E15VI0MB7LXV19
- Country:
- Sweden
- Address:
- C/O Medicon Village, 223 81 Lund
- Sector:
- Manufacturing
Description
Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-10-22 07:00 |
Alligator Bioscience focuses on ATOR-1017 and mitazalimab
|
English | 78.0 KB | ||
| 2020-10-22 07:00 |
Alligator Bioscience fokuserar på ATOR-1017 och mitazalimab
|
Swedish | 78.4 KB | ||
| 2020-09-28 13:15 |
Alligator Bioscience utser Gayle Mills till Chief Business Officer
|
Swedish | 75.9 KB | ||
| 2020-09-28 13:15 |
Alligator Bioscience appoints Gayle Mills as Chief Business Officer
|
English | 75.4 KB | ||
| 2020-09-24 16:45 |
Alligator Bioscience lanserar ett nytt immunonkologikoncept
|
Swedish | 86.6 KB | ||
| 2020-09-24 16:45 |
Alligator Bioscience launches a new immuno-oncology concept
|
English | 85.7 KB | ||
| 2020-09-16 08:30 |
Alligator Bioscience erhåller patent för läkemedelskandidaten ATOR-1015
|
Swedish | 94.2 KB | ||
| 2020-09-16 08:30 |
Alligator Bioscience receives patent approval for the drug candidate ATOR-1015
|
English | 94.2 KB | ||
| 2020-09-09 13:40 |
Alligator Bioscience ger en uppdatering gällande fas I-studien med läkemedelska…
|
Swedish | 98.8 KB | ||
| 2020-09-09 13:40 |
Alligator Bioscience presents an update regarding the Phase I study with the dr…
|
English | 98.9 KB | ||
| 2020-09-04 08:30 |
Alligator Bioscience presents positive biomarker data demonstrating proof of me…
|
English | 114.7 KB | ||
| 2020-09-04 08:30 |
Alligator Bioscience presenterar positiva biomarkördata från klinisk fas I-stud…
|
Swedish | 114.2 KB | ||
| 2020-08-27 08:30 |
Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Pha…
|
English | 101.7 KB | ||
| 2020-08-27 08:30 |
Alligator Bioscience: Lovande säkerhetsdata i klinisk fas I-studie med ATOR-1017
|
Swedish | 101.4 KB | ||
| 2020-08-25 11:00 |
Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day…
|
English | 102.1 KB |
Automate Your Workflow. Get a real-time feed of all Alligator Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alligator Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alligator Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-28 | Peter Ostler | Other | Sell | 1,658,134 | 179,045.31 SEK |
| 2024-04-11 | Staffan Encrantz | Other | Sell | 44,108,581 | 47,196,181.67 SEK |
| 2022-10-27 | Sören Bregenholt Frederiksen | Other | Buy | 52,000 | 72,748.00 SEK |
| 2022-10-25 | Marie Svensson | Other | Buy | 12,000 | 16,632.00 SEK |
| 2022-08-19 | Sören Bregenholt Frederiksen | Other | Buy | 13,906 | 25,726.10 SEK |
| 2022-08-18 | Sören Bregenholt Frederiksen | Other | Buy | 31,094 | 56,911.35 SEK |
| 2022-05-31 | Peter Ostler | Other | Buy | 100,000 | 151,500.00 SEK |
| 2022-05-04 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,895.00 SEK |
| 2022-05-02 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,811.00 SEK |
| 2022-04-30 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 51,171.00 SEK |
Peer Companies
